{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:44:20Z","timestamp":1794962660569,"version":"4.9.1"},"reference-count":41,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Sickle cell disease (SCD), one of the most common monogenetic diseases in the world, is associated with multisystemic complications that begin in childhood. Most of the babies homozygous for the sickle haemoglobin gene are born in sub-Saharan Africa. Over the years, progress has been made with early diagnosis through newborn screening, penicillin prophylaxis, pneumococcal immunisation, transcranial Doppler (TCD) screening, hydroxyurea therapy and chronic blood transfusions with remarkably improved survival and quality of life of children with SCD. However, wide disparities in outcomes exist between high-income countries (HICs) where over 90% survive to adulthood, and low-income and middle-income countries (LMICs) where less than half achieve that milestone. Even in HICs, racial inequities pose barriers to accessing specialised care and receiving treatment for acute pain episodes. Better understanding of SCD pathophysiology is being exploited to develop new disease-modifying drugs and gene therapy approaches to further improve outcomes. Bone marrow transplantation is established as a curative treatment for SCD, but it is largely unavailable in LMICs. To bridge the disparity and inequity gaps, innovative approaches are needed in LMICs. Validated and more affordable, easy-to-use point-of-care tests offer opportunities to link early diagnosis with immunisation programmes and healthcare encounters. Widespread use of hydroxyurea therapy\u2014a relatively affordable and effective disease-modifying drug\u2014in LMICs would help improve survival and quality of life. Integration of SCD treatment into primary care linked to district level\/provincial hospitals that are supported with evidence-based guidelines will help extend needed interventions to many more patients living in LMICs.<\/jats:p>","DOI":"10.1136\/archdischild-2021-323633","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T17:25:55Z","timestamp":1655313955000},"page":"108-114","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Sickle cell disease in children: an update of the evidence in low- and middle-income settings"],"prefix":"10.1136","volume":"108","author":[{"given":"Isaac","family":"Odame","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"2023051801501146000_108.2.108.1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N Engl J Med Overseas Ed"},{"key":"2023051801501146000_108.2.108.2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1104"},{"key":"2023051801501146000_108.2.108.3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001484"},{"key":"2023051801501146000_108.2.108.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: a neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"Am J Prev Med"},{"key":"2023051801501146000_108.2.108.5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10937"},{"key":"2023051801501146000_108.2.108.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-233700"},{"key":"2023051801501146000_108.2.108.7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jamapediatrics.2015.4276","article-title":"Global and national burden of diseases and injuries among children and adolescents between 1990 and 2013: findings from the global burden of disease 2013 study","volume":"170","author":"Kyu","year":"2016","journal-title":"JAMA Pediatr"},{"key":"2023051801501146000_108.2.108.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-498311"},{"key":"2023051801501146000_108.2.108.9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/1871529X10909040271","article-title":"A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemoprophylaxis","volume":"9","author":"Hebbel","year":"2009","journal-title":"Cardiovasc Hematol Drugs Targets"},{"key":"2023051801501146000_108.2.108.10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bcmd.2017.08.010","article-title":"The pressing need for point-of-care diagnostics for sickle cell disease: a review of current and future technologies","volume":"67","author":"McGann","year":"2017","journal-title":"Blood Cells Mol Dis"},{"key":"2023051801501146000_108.2.108.11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/17434440.2016.1254038","article-title":"Emerging point-of-care technologies for sickle cell disease screening and monitoring","volume":"13","author":"Alapan","year":"2016","journal-title":"Expert Rev Med Devices"},{"key":"2023051801501146000_108.2.108.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198606193142501"},{"key":"2023051801501146000_108.2.108.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70154-0"},{"key":"2023051801501146000_108.2.108.14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6430.1567"},{"key":"2023051801501146000_108.2.108.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6430.1567"},{"key":"2023051801501146000_108.2.108.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70055-4"},{"key":"2023051801501146000_108.2.108.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.1997.d01-322.x"},{"key":"2023051801501146000_108.2.108.18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-233528"},{"key":"2023051801501146000_108.2.108.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.10517"},{"key":"2023051801501146000_108.2.108.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199505183322001"},{"key":"2023051801501146000_108.2.108.21","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960","article-title":"Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial","volume":"88","author":"Ferster","year":"1996","journal-title":"Blood"},{"key":"2023051801501146000_108.2.108.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60355-3"},{"key":"2023051801501146000_108.2.108.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788935"},{"key":"2023051801501146000_108.2.108.24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001851"},{"key":"2023051801501146000_108.2.108.25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23547"},{"key":"2023051801501146000_108.2.108.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401731"},{"key":"2023051801501146000_108.2.108.27","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.119593"},{"key":"2023051801501146000_108.2.108.28","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood.V89.5.1787","article-title":"Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative study of sickle cell disease","volume":"89","author":"Vichinsky","year":"1997","journal-title":"Blood"},{"key":"2023051801501146000_108.2.108.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006223422502"},{"key":"2023051801501146000_108.2.108.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390102"},{"key":"2023051801501146000_108.2.108.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050460"},{"key":"2023051801501146000_108.2.108.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01041-7"},{"key":"2023051801501146000_108.2.108.33","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/bloodadvances.2019001142","article-title":"American Society of hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults","volume":"4","author":"DeBaun","year":"2020","journal-title":"Blood Adv"},{"key":"2023051801501146000_108.2.108.34","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S2352-3026(21)00368-9","article-title":"Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (spring): a double-blind, multicentre, randomised, phase 3 trial","volume":"9","author":"Abdullahi","year":"2022","journal-title":"Lancet Haematol"},{"key":"2023051801501146000_108.2.108.35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-392340"},{"key":"2023051801501146000_108.2.108.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971"},{"key":"2023051801501146000_108.2.108.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"2023051801501146000_108.2.108.38","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of Voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"key":"2023051801501146000_108.2.108.39"},{"key":"2023051801501146000_108.2.108.40","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"Crispr-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"key":"2023051801501146000_108.2.108.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2021-323633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T08:53:27Z","timestamp":1684400007000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2021-323633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,1,19]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/archdischild-2021-323633"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2021-323633","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]}}}